Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

First phase III trial of HspE7 commences in anal dysplasia

Nov. 9, 2000

Update on worldwide phase III trials of Maxamine

Nov. 9, 2000

Maxamine protects against IL-2 toxicity in murine model

Nov. 8, 2000

Seattle Genetics evaluates SGN-15/Taxotere combination in phase II

Nov. 7, 2000

KS Biomedix and York Medical sign high-affinity antibody deal

Nov. 7, 2000

KRN-7000 as an adjunct to surgical removal of tumors

Nov. 3, 2000

Xoma initiates phase I trial with ING-1 monoclonal antibody

Nov. 2, 2000

Melacine as adjuvant therapy in melanoma: phase III data reported at SBT meeting

Oct. 30, 2000

Immunotherapy with beta-alethine useful in minimal residual disease

Oct. 30, 2000

Therion and Aventis expand cancer vaccine alliance

Oct. 27, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 1, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
CINP 2026: Gut microbiota could predict antidepressant response
BioWorld
The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to...
Ascending BCI systems deepen national security, ethical concerns
BioWorld
Ready or not, the future has arrived. Novel AI and brain-computer interface (BCI) systems are no longer confined to the realm of science fiction. As an...
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...